Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Clin Cancer Res. 2010 Dec 1;16(23):5835-41. doi: 10.1158/1078-0432.CCR-10-1434. Epub 2010 Oct 18.
Metabolomics is a new, rapidly expanding field dedicated to the global study of metabolites in biological systems. In this article metabolomics is applied to find urinary biomarkers for breast and ovarian cancer.
Urine samples were collected from early- and late-stage breast and ovarian cancer patients during presurgical examinations and randomly from females with no known cancer. After quantitatively measuring a set of metabolites using nuclear magnetic resonance spectroscopy, both univariate and multivariate statistical analyses were employed to determine significant differences.
Metabolic phenotypes of breast and ovarian cancers in comparison with normal urine and with each other revealed significance at Bonferroni-corrected significance levels resulting in unique metabolite patterns for breast and ovarian cancer. Intermediates of the tricarboxylic acid cycle and metabolites relating to energy metabolism, amino acids, and gut microbial metabolism were perturbed.
The results presented here illustrate that urinary metabolomics may be useful for detecting early-stage breast and ovarian cancer.
代谢组学是一个新兴的、快速发展的领域,致力于对生物系统中的代谢物进行全面研究。本文将代谢组学应用于寻找乳腺癌和卵巢癌的尿生物标志物。
在术前检查期间,从早期和晚期乳腺癌和卵巢癌患者以及无已知癌症的女性中随机收集尿液样本。使用核磁共振波谱法定量测量一组代谢物后,采用单变量和多变量统计分析来确定显著差异。
与正常尿液和彼此相比,乳腺癌和卵巢癌的代谢表型在经过 Bonferroni 校正的显著水平上具有显著性,导致乳腺癌和卵巢癌具有独特的代谢物模式。三羧酸循环的中间产物以及与能量代谢、氨基酸和肠道微生物代谢相关的代谢物受到干扰。
本文的结果表明,尿代谢组学可能有助于检测早期乳腺癌和卵巢癌。